E2F1-regulated USP5 contributes to the tumorigenic capacity of glioma stem cells through the maintenance of OCT4 stability
Cancer Letters · 2024-07 · 593 · 216875
DOI: 10.1016/j.canlet.2024.216875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-07. Verfasst von Xiao Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Electronic address: jian…. Hauptthemen laut MEDLINE: Octamer Transcription Factor-3, Neoplastic Stem Cells, E2F1 Transcription Factor, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Mesenchymal glioma stem cells (MES GSCs) are a subpopulation of cells in glioblastoma (GBM) that contribute to a worse prognosis owing to their highly aggressive nature and resistance to radiation therapy. Here, OCT4 is characterized as a critical factor in sustaining the stemness phenotype of MES GSC. We find that OCT4 is expressed intensively in MES GSC and is intimately associated with poor prognosis, moreover, OCT4 depletion leads to diminished invasive capacity and impairment of the stem phenotype in MES GSC. Subsequently, we demonstrated that USP5 is a deubiquitinating enzyme which directly interacts with OCT4 and preserves OCT4 stability through its deubiquitination. USP5 was additionally proven to be aberrantly over-expressed in MES GSCs, and its depletion resulted in a noticeable diminution of OCT4 and consequently a reduced self-renewal and tumorigenic capacity of MES GSCs, which can be substantially restored by ectopic expression of OCT4. In addition, we detected the dominant molecule that regulates USP5 transcription, E2F1, with dual luciferase reporter gene analysis. In combination, targeting the E2F1-USP5-OCT4 axis is a potentially emerging strategy for the therapy of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Electronic address: jiangxiao1022@163.com.
- Department of Neurosurgery, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Electronic address: youhongtoo@163.com.
- Department of Neurosurgery, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Electronic address: YIniuyx13131161939@163.com.
- Translational Medicine Research Center, Zhujiang Hospital of Southern Medical University, 510280, Guangdong Province, China. Electronic address: dingyudan2021@163.com.
- Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China. Electronic address: czx11360@163.com.
- Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China. Electronic address: hbwang@njmu.edu.cn.
Zitieren
APA
Jiang, X., You, H., Niu, Y., Ding, Y., Chen, Z., Wang, H., Xu, Y., Zhou, P., Wei, L., Deng, D., Xue, L., Peng, Y., Yang, Y., Fan, L., & Shao, N. (2024). E2F1-regulated USP5 contributes to the tumorigenic capacity of glioma stem cells through the maintenance of OCT4 stability. Cancer Letters, 593, 216875. https://doi.org/10.1016/j.canlet.2024.216875
Vancouver
Jiang X, You H, Niu Y, Ding Y, Chen Z, Wang H, et al. E2F1-regulated USP5 contributes to the tumorigenic capacity of glioma stem cells through the maintenance of OCT4 stability. Cancer Letters. 2024;593:216875. doi:10.1016/j.canlet.2024.216875
BibTeX
@article{Jiang2024,
author = {Jiang, Xiao and You, Hongtao and Niu, Yixuan and Ding, Yudan and Chen, Zhengxin and Wang, Huibo and Xu, Yuan and Zhou, Peng and Wei, Li and Deng, Danni and Xue, Lian and Peng, Ya and Yang, Yilin and Fan, Ligang and Shao, Naiyuan},
title = {E2F1-regulated USP5 contributes to the tumorigenic capacity of glioma stem cells through the maintenance of OCT4 stability},
journal = {Cancer Letters},
year = {2024},
volume = {593},
pages = {216875},
doi = {10.1016/j.canlet.2024.216875}
}
EUVIMED